AbbVie (ABBV) Q4 FY2025 earnings: revenue $16.6 billion, up 10.0% on the year
AbbVie Inc. (ABBV) reported revenue of $16.6 billion for Q4 FY2025, the quarter ended 31 December 2025, up 10.0% on the same quarter a year earlier. Net income was $1.8 billion, and diluted earnings per share $1.02. The figures are the company's own, from the 10-K it filed with the SEC on 20 February 2026.
Revenue
$16.6 billion
+10.0% on the year · +5.3% on the quarter
Q1 FY2024Q4 FY2025
Operating margin
27.3%
-9.9% a year earlier
Q1 FY2024Q4 FY2025
Net income
$1.8 billion
+876.3% on the quarter
Q1 FY2024Q4 FY2025
Diluted EPS
$1.02
+920.0% on the quarter
Q1 FY2024Q4 FY2025
this quarterthe same quarter a year earlierHover a bar for its figure.
Income statement (profit and loss)
$ million
Q4 FY2025
Q3 FY2025
Q4 FY2024
On the quarter
On the year
Last 8 quarters
Revenue
16,618
15,776
15,102
+5.3%
+10.0%
Cost of revenue
4,552
5,304
4,396
-14.2%
+3.5%
Gross profit
12,066
10,472
10,706
+15.2%
+12.7%
Gross margin
72.6%
66.4%
70.9%
Research and development
2,579
2,319
6,774
+11.2%
-61.9%
Selling, general and administrative
3,895
3,569
3,855
+9.1%
+1.0%
Operating income
4,544
1,904
-1,490
+138.7%
Operating margin
27.3%
12.1%
-9.9%
Interest expense
714
739
702
-3.4%
+1.7%
Pre-tax income
2,668
714
-2,269
+273.7%
Income tax
853
526
-2,246
+62.2%
Effective tax rate
32.0%
73.7%
n/a
Net income
1,816
186
-22.0
+876.3%
Net margin
10.9%
1.2%
-0.1%
Diluted EPS
$1.02
$0.10
-$0.02
+920.0%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q4 FY2025
Q3 FY2025
Q4 FY2024
On the quarter
On the year
Last 8 quarters
Operating cash flow
5,218
7,024
7,048
-25.7%
-26.0%
Capital expenditure
329
381
291
-13.6%
+13.1%
Free cash flow
4,889
6,643
6,757
-26.4%
-27.6%
Free cash flow margin
29.4%
42.1%
44.7%
Cash from investing
-1,463
-3,264
-1,874
Cash from financing
-4,166
-4,590
-6,861
Depreciation and amortisation
1,922
2,092
2,137
-8.1%
-10.1%
Share-based compensation
157
209
164
-24.9%
-4.3%
Buybacks
3.0
4.0
358
-25.0%
-99.2%
Dividends paid
2,911
2,911
2,752
0.0%
+5.8%
Dividend per share
$1.73
$1.64
$1.64
+5.5%
+5.5%
Diluted shares, weighted
n/a
1,772m
n/a
Shares outstanding at period end
1,768m
1,767m
1,765m
+0.0%
+0.2%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q4 FY2025
Q3 FY2025
Q4 FY2024
On the quarter
On the year
Last 8 quarters
Shareholders' equity
-3,270
-2,642
3,325
Non-controlling interest
42.0
43.0
39.0
-2.3%
+7.7%
Short-term borrowings
n/a
n/a
0.0
Debt
67,496
68,743
66,841
-1.8%
+1.0%
Operating lease liabilities
689
n/a
697
-1.1%
Finance lease liabilities
22.0
n/a
23.0
-4.3%
Other liabilities
68,981
67,754
64,236
+1.8%
+7.4%
Total liabilities and equity
133,960
133,898
135,161
+0.0%
-0.9%
Fixed assets
5,628
5,483
5,134
+2.6%
+9.6%
Goodwill
35,640
35,626
34,956
+0.0%
+2.0%
Intangible assets
52,641
54,315
60,068
-3.1%
-12.4%
Investments
296
333
310
-11.1%
-4.5%
Cash and equivalents
5,229
5,629
5,524
-7.1%
-5.3%
Receivables
12,589
12,769
10,919
-1.4%
+15.3%
Inventory
4,951
4,938
4,181
+0.3%
+18.4%
Other assets
16,986
14,805
14,069
+14.7%
+20.7%
Total assets
133,960
133,898
135,161
+0.0%
-0.9%
Questions
What was AbbVie's revenue in Q4 FY2025?
AbbVie (ABBV) reported revenue of $16.6 billion for Q4 FY2025, the quarter ended 31 December 2025, up 10.0% on the same quarter a year earlier.
How much did AbbVie earn in Q4 FY2025?
Net income for Q4 FY2025 was $1.8 billion, and diluted earnings per share $1.02.
When did AbbVie report Q4 FY2025 results?
AbbVie filed its 10-K for the quarter ended 31 December 2025 with the SEC on 20 February 2026.
Each quarter as filed, linked to its filing. Read moreMoney is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-K for the period ended 31 December 2025, filed 20 February 2026: the filing.